Comparative Outcomes of Idecabtagene Vicleucel in Relapse and Refractory Multiple Myeloma Patients with and without Prior BCMA Therapy: A CIBMTR Real-World Analysis

Key Points

• Outcomes vary significantly between patients with prior BCMA therapy and those without.
• The analysis involved retrospective data from the CIBMTR registry focusing on treatment response.
• Patients without prior BCMA therapy exhibited distinct clinical trajectories compared to those with past treatment.
• This real-world analysis highlights the nuanced effectiveness of idecabtagene vicleucel across treatment histories.